CD30+ leukemic cutaneous T-cell lymphoma - 11/01/21
Doi : 10.1016/j.jaad.2020.05.014
Ariana Ellis, BS a, b, ⁎ 
, Luisa F. Christensen, MD b, Timmie Sharma, MD b, Howard Meyerson, MD c, Honda Kord, MD b, Kevin D. Cooper, MD b
, Luisa F. Christensen, MD b, Timmie Sharma, MD b, Howard Meyerson, MD c, Honda Kord, MD b, Kevin D. Cooper, MD b a Northeast Ohio Medical University, Rootstown, Ohio
b Department of Dermatology, University Hospitals Cleveland Medical Center/Case Western Reserve University School of Medicine, Cleveland, Ohio
c Department of Pathology, University Hospitals Case Medical Center and Seidman Cancer Center Case Western Reserve University, Cleveland, Ohio
∗Correspondence to: Ariana Ellis, BS, Northeast Ohio Medical University, 5901 Sharon Dr, Boardman, OH 44512Northeast Ohio Medical University5901 Sharon DrBoardmanOH44512
| Funding sources: None. |
|
| Disclosure: Dr Cooper receives honoraria for consulting and serving on the advisory board for Novartis, Menlo, Meiji Seika Pharma, and Almirall and is a principal investigator and receives funding from Pfizer (fellowship grant), Soligenix (sponsored study), Celgene, and Cort (National Institutes of Health–funded clinical trial). Author Ellis and Drs Christensen, Sharma, Meyerson, and Kord have no conflicts of interest to declare. |
|
| IRB approval status: Reviewed and approved by University Hospitals Case Medical Center (approval no. 10-17-09C). |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 84 - N° 2
P. 530-532 - février 2021 Retour au numéro
Article précédent
- Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses
- Louis Y. Tee, Rehena Sultana, Steve Y.C. Tam, Choon Chiat Oh
- The association of frontal fibrosing alopecia with skin and hair care products: A survey-based case series of 56 patients seen at the Mayo Clinic
- Reese L. Imhof, Sydney C. Larkin, Hafsa M. Cantwell, Rochelle R. Torgerson, Stanislav N. Tolkachjov
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?